Neutropenia is a known class effect associated with CDK4/6 inhibitors1,2
Unlike chemotherapy, neutropenia with CDK4/6 inhibitors is cytostatic not cytotoxic1,2
Incidence and management of neutropenia in EBC and MBC1
Across KISQALI phase III studies, most neutropenia-related AEs occurred early during treatment, and were resolved quickly with recommended dose modifications.1
FBC monitoring schedule1
Neutropenia management algorithm1
†Grading according to CTCAE Version 5.03
PBS Information: Authority Required. For the treatment of advanced/metastatic breast cancer and early breast cancer at high risk of recurrence meeting PBS criteria. Refer to the PBS Schedule for full Authority information.
Please see approved Product Information before prescribing. Approved Product Information available on request. For the most up to date Product Information go to https://www.novartis.com.au/products/healthcare-professionals/products
Neutropenia is a grouped term that combines the preferred terms neutropenia and neutrophil count decreased1
Abbreviations: AE, adverse event; ANC, absolute neutrophil count; cyclin-dependent kinases 4 and 6; CTCAE, Common Terminology Criteria for Adverse Events; EBC, early breast cancer; ECG, electrocardiogram; FBC, full blood count; LFT, liver function test; LHRH, luteinising hormone-releasing hormone; LLN, lower limit of normal; MBC, metastatic breast cancer; N, number of patients; ULN, upper limit of normal.
References
1. KISQALI approved Product Information. 2. Stanciu IM, et al. Biomolecules. 2023; 13(9):1422. 3. Common Terminology Criteria
for Adverse Events (CTCAE), National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov.
Accessed June 2026.
© 2026 Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. Sydney NSW.
For medical enquiries please contact 1 800 671 203 or [email protected].